Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Pfizer Inc. (NYSE:PFE) has unveiled major advances in cancer research at the 2025 ASCO Annual Meeting, spotlighting robust ...

Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

In the latest trading session, Pfizer (PFE) closed at $22.15 ... these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this ...

The market seems to be waking up on Pfizer's recovery prospects ... particularly evidenced by its recent quarter performance - I think that the stock should continue to be rated as a "Buy".

The remarkable improvement was driven by the strong performance of Pfizer's core portfolio ... and then choose between a market order or a limit order to buy the stock. To sell shares of Pfizer ...

It compares these trends to the stock’s performance during the 2008 recession. In contrast, here’s how PFE stock and the broader market performed during the 2007/2008 crisis. PFE stock ...

The the stock of drugmaker has fallen by 11.82% ... The investment community will be paying close attention to the earnings performance of Pfizer in its upcoming release. The company is slated ...

The drugmaker's stock has dropped by 15.91% in the past month, falling short of the Medical sector's loss of 8.46% and the S&P 500's loss of 6.3%. The investment community will be paying close ...